PNA Nanoparticles for Gene Editing In Vivo

用于体内基因编辑的 PNA 纳米颗粒

基本信息

  • 批准号:
    9804726
  • 负责人:
  • 金额:
    $ 42.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-05 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

There is substantial interest in gene editing as a potential means to treat human genetic disorders such as thalassemia and sickle cell disease. Much effort has been focused on targeted nucleases such as CRISPR/Cas9 and zinc-finger nucleases (ZFNs), based on work showing that site-directed DNA damage strongly promotes homologous recombination (HR). However, clinical application of targeted nucleases is challenged by the risk of off-target cleavage events in the genome. As an alternative, in work recently published in Nature Communications, the Ly, Saltzman, and Glazer labs have shown that γ-substituted triplex- forming peptide nucleic acids (PNAs) and donor DNAs delivered intravenously (IV) via poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) into a mouse model of human β-thalassemia produced almost complete amelioration of the disease, with clinically relevant β-globin gene correction frequencies in hematopoietic stem cells (HSCs) of up to 7%. The mice showed alleviation of anemia, improvement in RBC morphologies, and reversal of splenomegaly and extramedullary hematopoiesis, with extremely low off-target effects in the genome, a key advantage of this technology. The other key advantage is that the components can be synthesized chemically and formulated into nanoparticles for simple IV administration. However, synthesis of γPNAs is complicated and expensive, and they are not commercially available, limiting the ability of investigators to exploit this technology. In line with RFA-RM-18-024, “Expanding the Human Genome Engineering Repertoire”, this multi-PI proposal by Ly, Saltzman, and Glazer seeks to advance PNA/NP-based gene editing by simplifying and scaling up PNA synthesis, by incorporating next generation PNA chemistry to boost binding affinity, increase selectivity, and enhance potency, and by strategically exploiting cellular DNA repair pathways. The Specific Aims are: (1) To scale up PNA production and augment DNA binding, in order to expedite the translation of PNAs for therapeutic gene editing and enable widespread adoption of the technology. We will devise an enantioselective strategy for scaling up the production of monomers, and we will synthesize and test γPNAs with modified nucleobases to achieve improved DNA binding properties and to overcome the homopurine sequence restriction for triplex formation. (2) To develop strategies to manipulate DNA repair to enhance the efficiency of PNA-mediated gene editing, based on promising preliminary results with a novel DNA repair inhibitor. (3) To provide a robust platform of assays to evaluate the advancements from Aims 1-2 and to generalize this approach to multiple genes. We will continue to exploit facile mouse- and cell-based assays for correction of the human β-globin gene at the IVS2-654 thalassemia mutation. We expect this work to provide the basis for designing even more potent PNAs applicable to gene editing for many human genetic disorders.
人们对基因编辑作为治疗人类遗传疾病的潜在手段有很大的兴趣, 地中海贫血和镰状细胞病。许多努力都集中在靶向核酸酶上, CRISPR/Cas9和锌指核酸酶(ZFN),基于显示定点DNA损伤 强烈促进同源重组(HR)。然而,靶向核酸酶的临床应用受到限制。 受到基因组中脱靶切割事件风险的挑战。作为替代,在最近的工作中, 发表在《自然通讯》上,Ly,Saltzman和Glazer实验室已经表明,γ-取代的三链体- 形成肽核酸(PNA)和供体DNA,通过聚(乳酸-共-乙醇酸)静脉内(IV)递送 酸(PLGA)纳米颗粒(NPs)进入人β-地中海贫血小鼠模型产生几乎完全 改善疾病,造血干细胞中临床相关的β-珠蛋白基因校正频率 细胞(HSC)高达7%。小鼠表现出贫血的缓解,RBC形态的改善, 脾肿大和髓外造血的逆转,在 基因组是这项技术的一个关键优势。另一个主要优点是,组件可以 化学合成并配制成纳米颗粒用于简单的IV给药。然而,合成 γ PNA是复杂且昂贵的,并且它们不是商业上可获得的,限制了γ PNA的能力。 调查人员正在利用这项技术。根据RFA-RM-18-024,“扩展人类基因组 Ly、Saltzman和Glazer的多PI提案旨在推进基于PNA/NP的 通过简化和扩大PNA合成的基因编辑,通过结合下一代PNA化学, 增强结合亲和力,增加选择性,增强效力,并通过战略性地利用细胞DNA 修复路径。具体目的是:(1)扩大PNA的生产并增强DNA结合,以 加快用于治疗性基因编辑的PNA的翻译,并使 技术.我们将设计一种对映选择性策略来扩大单体的生产,我们将 合成和测试具有修饰的核碱基的γ PNA,以实现改进的DNA结合特性, 克服了三链体形成的同型嘌呤序列限制。(2)制定策略来操纵 DNA修复以提高PNA介导的基因编辑的效率,基于有希望的初步结果 一种新型DNA修复抑制剂(3)提供一个强大的检测平台,以评估 目的1-2,并将这种方法推广到多个基因。我们将继续利用简易鼠标-和 用于校正IVS 2 -654地中海贫血突变的人β-珠蛋白基因的基于细胞的测定。我们预计 这项工作为设计适用于许多人类基因编辑的更有效的PNA提供了基础。 遗传疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER M GLAZER其他文献

PETER M GLAZER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER M GLAZER', 18)}}的其他基金

PNA Nanoparticles for Gene Editing In Vivo
用于体内基因编辑的 PNA 纳米颗粒
  • 批准号:
    10198735
  • 财政年份:
    2019
  • 资助金额:
    $ 42.11万
  • 项目类别:
PNA Nanoparticles for Gene Editing In Vivo
用于体内基因编辑的 PNA 纳米颗粒
  • 批准号:
    10414795
  • 财政年份:
    2019
  • 资助金额:
    $ 42.11万
  • 项目类别:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
用于将基因编辑剂体内靶向递送至骨髓和肺的聚(胺-共酯)
  • 批准号:
    10274829
  • 财政年份:
    2018
  • 资助金额:
    $ 42.11万
  • 项目类别:
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung
用于将基因编辑剂体内靶向递送至骨髓和肺的聚(胺-共酯)
  • 批准号:
    10706300
  • 财政年份:
    2018
  • 资助金额:
    $ 42.11万
  • 项目类别:
Poly(amine-co-ester)s for targeted delivery of gene editing agents to treat cystic fibrosis in animal models: SCGE Disease Models Studies Supplement
用于靶向递送基因编辑剂以治疗动物模型中的囊性纤维化的聚(胺共酯):SCGE 疾病模型研究补充
  • 批准号:
    10619840
  • 财政年份:
    2018
  • 资助金额:
    $ 42.11万
  • 项目类别:
Novel DNA Repair Inhibitors for Cancer Therapy
用于癌症治疗的新型 DNA 修复抑制剂
  • 批准号:
    9388067
  • 财政年份:
    2017
  • 资助金额:
    $ 42.11万
  • 项目类别:
Novel DNA Repair Inhibitors for Cancer Therapy
用于癌症治疗的新型 DNA 修复抑制剂
  • 批准号:
    10204894
  • 财政年份:
    2017
  • 资助金额:
    $ 42.11万
  • 项目类别:
Novel DNA Repair Inhibitors for Cancer Therapy
用于癌症治疗的新型 DNA 修复抑制剂
  • 批准号:
    10456727
  • 财政年份:
    2017
  • 资助金额:
    $ 42.11万
  • 项目类别:
Novel DNA Repair Inhibitors for Cancer Therapy
用于癌症治疗的新型 DNA 修复抑制剂
  • 批准号:
    9981673
  • 财政年份:
    2017
  • 资助金额:
    $ 42.11万
  • 项目类别:
Yale Cancer Biology Training Grant
耶鲁大学癌症生物学培训补助金
  • 批准号:
    10170726
  • 财政年份:
    2016
  • 资助金额:
    $ 42.11万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.11万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 42.11万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 42.11万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了